TD Cowen lowered the firm’s price target on Quanterix (QTRX) to $11 from $15 and keeps a Hold rating on the shares. The firm noted they announced the acquisition of Akoya Biosciences (AKYA) (AKYA ). Cowen said the deal is highly dilutive and while there is ample strategic/financial merit for the deal they see it adding more risk/uncertainty to the Quanterix story just at the point where the stand-alone outlook was set to improve in 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix Announces Merger with Akoya Biosciences
- Quanterix Merges with Akoya for Enhanced Biomarker Solutions
- Quanterix to acquire Akoya Biosciences in an all-stock transaction
- Down More Than 60%: Analysts Expect These 2 Beaten-Down Stocks to Rebound in 2025
- Quanterix Expands with Acquisition of Emission Inc.